Avita Medical, Inc. Common Stock (RCEL)

AVITA Medical experienced significant stock decline after revealing a six-month backlog in unpaid provider claims for Recell procedures, caused by Medicare & Medicaid Services' pricing and claims adjudication issues.

Avita Medical reported Q2 2025 earnings with commercial revenue rising 21% to $18.4 million, but missing consensus estimates due to Medicare reimbursement delays. The company reduced its full-year revenue guidance and delayed profitability expectations.

AVITA Medical (NASDAQ:RCEL) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 3 1 0 0 Last 30D 0 1 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 2 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $19.0, a high estimate of $25.00, and a low estimate of $9.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 9.52%. Decoding Analyst Ratings: A Detailed Look The standing of AVITA Medical among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Matt O'Brien Piper Sandler Lowers Neutral $9.00 $21.00 Ross Osborn Cantor Fitzgerald Lowers Overweight $21.00 $22.00 Matt O'Brien Piper Sandler Raises Overweight $21.00 $19.00 Ross Osborn Cantor Fitzgerald Raises Overweight $25.00 $22.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to AVITA Medical. This offers insight into analysts' perspectives on the current state of the company. Rating: Analyzing trends, analysts ...Full story available on Benzinga.com

Avita's (RCEL) stock declines 19% after the company lowered its total revenue guidance for 2023.